SCVPY yields 2.22% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 5
Combined, SCVPY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SCVPY + JNJ for your $10,000?
The Siam Cement Public Company Limited, together with its subsidiaries, engages in the cement and building materials, chemicals, and packaging businesses in Thailand, Vietnam, Indonesia, China, and internationally. The company operates through Cement-Building Materials Business, Chemicals Business, Packaging Business, and Other segments. The Cement-Building Materials Business segment manufactures and distributes grey cement, ready-mixed concrete, white cement, dry mortar, roof tiles, ceiling and wall boards, wood substitutes, concrete paving blocks, ceramic tiles, and sanitary wares and fittings. This segment also distributes cement, building, and decorative products for home and residence through omni channel; and offers logistics, delivery, and import and export services. The Chemicals Business segment manufactures and sells olefins, polyolefins, and vinyl and other chemical products. The Packaging Business segment provides fiber-based, paper and performance, and polymer packaging products; foodservice products; and pulp and paper products comprising primarily printing and writing paper and pulp. The Other segment invests primarily in agricultural machines, automotive parts and components, steel, clean energy business, and other technologies, as well as automation system integration business and other services. The Siam Cement Public Company Limited was founded in 1913 and is headquartered in Bangkok, Thailand.
Full SCVPY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.